EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder

被引:83
作者
Brunner, A. [1 ]
Prelog, M. [2 ]
Verdorfer, I. [1 ]
Tzankov, A. [3 ]
Mikuz, G. [1 ]
Ensinger, C. [1 ]
机构
[1] Med Univ Innsbruck, Inst Pathol, Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Pediat, Innsbruck, Austria
[3] Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland
关键词
D O I
10.1136/jcp.2007.049460
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
Background: EpCAM is an adhesion molecule of the basolateral membranes in a variety of epithelial cells. Over-expression has been detected in many epithelial tumours and has been associated with high stage, high grade and a worse survival in some tumour types. Aims: To assess the prognostic value of EpCAM in urothelial carcinoma of the bladder. Methods: EpCAM expression was analysed by immunohistochemistry using a monoclonal antibody ( clone VU-1D9) on a tissue microarray comprising 99 urothelial carcinomas of the bladder diagnosed between 1994 and 1997. Results: A significant relationship between high grade, advanced stage, and EpCAM expression was found, and expression of EpCAM was associated with a worse overall survival when compared to EpCAM negative tumours (p= 0.033). Multivariate analysis showed that EpCAM expression was not an independent prognostic factor for overall survival in urothelial carcinoma of the bladder. Conclusion: EpCAM expression is associated with advanced stage, high grade and poor overall survival in urothelial carcinoma of the bladder, but lacks an independent prognostic significance. The strong association with high grade tumours suggests a possible role during tumour progression and makes EpCAM a potential target for antibody mediated therapy.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 33 条
[1]
ANAGNOSTAKI E, 1990, BRIT J CANCER, V62, P52
[2]
EpCAM (CD326) finding its role in cancer [J].
Baeuerle, P. A. ;
Gires, O. .
BRITISH JOURNAL OF CANCER, 2007, 96 (03) :417-423
[3]
The biology of the 17-1A antigen (Ep-CAM) [J].
Balzar, M ;
Winter, MJ ;
de Boer, CJ ;
Litvinov, SV .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (10) :699-712
[4]
Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer [J].
Brunner, A. ;
Ensinger, C. ;
Christiansen, M. ;
Heiss, S. ;
Verdorfer, I. ;
Mikuz, G. ;
Tzankov, A. .
VIRCHOWS ARCHIV, 2007, 450 (06) :659-664
[5]
EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges [J].
Chaudry, M. A. ;
Sales, K. ;
Ruf, P. ;
Lindhofer, H. ;
Winslet, M. C. .
BRITISH JOURNAL OF CANCER, 2007, 96 (07) :1013-1019
[6]
EpCAM overexpression in thyroid carcinomas - A histopothological study of 121 cases [J].
Ensinger, Christian ;
Kremser, Roswitha ;
Prommegger, Rupert ;
Spizzo, Gilbert ;
Schmid, Kurt W. .
JOURNAL OF IMMUNOTHERAPY, 2006, 29 (05) :569-573
[7]
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance [J].
Fong, D. ;
Steurer, M. ;
Obrist, P. ;
Barbieri, V. ;
Margreiter, R. ;
Amberger, A. ;
Laimer, K. ;
Gastl, G. ;
Tzankov, A. ;
Spizzo, G. .
JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (01) :31-35
[8]
Ep-CAM overexpression in breast cancer as a predictor of survival [J].
Gastl, G ;
Spizzo, G ;
Obrist, P ;
Dünser, M ;
Mikuz, G .
LANCET, 2000, 356 (9246) :1981-1982
[9]
Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism [J].
Heideman, DAM ;
Van Beusechem, VW ;
Offerhaus, GJA ;
Wickham, TJ ;
Roelvink, PW ;
Craanen, ME ;
Pinedo, HM ;
Meijer, CJLM ;
Gerritsen, WR .
HUMAN GENE THERAPY, 2002, 13 (14) :1677-1685
[10]
Kimura H, 2007, INT J ONCOL, V30, P171